Investor Relations

HOME>Investor Relations

Open Up the Future　医療の未来を切り開く

Top Interview
Talk about the "Medium-Term Management Plan 16-20"

President & Representative Director
Masayuki Mitsuka

Interviewer: Economic caster Yuka Tanimoto

IR Calendar

2018

July 30: Announcement of FY2018 1st Quater Financial Results

June 22: The 11th Ordinary General Meeting of Shareholders

May 9: Announcement of FY2017 Financial Results

IR Calendar list

What's New

2018

July 30		IR Meeting for FY2018 1st Quarter Business Results[Material][Audio]
July 30		Announcement of FY2018 1st Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
July 27		Mitsubishi Tanabe Pharma's MT-7117 Receives U.S. FDA Fast Track Designation for the Investigational Treatment of Patients with the Ultra-Rare Disease, Erythropoietic Protoporphyria
July 19		Mitsubishi Tanabe Pharma Receives The 43rd (FY2018) Inoue Harushige Prize ― A challenge for the new drug against amyotrophic lateral sclerosis (ALS), research and development of edaravone―
July 2		Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” - Toward the Innovative Drug Discovery for refractory Neurological Diseases -
July 2		Open Call for Applicants for Researcher-Initiated Clinical Research Funds - We Ensure Transparency and Support Investigator-Initiated Research Based on Japan's Clinical Research Act -
June 28		Mitsubishi Tanabe Pharma and Janssen Pharmaceutical　K.K. update co-promotion framework for STELARA, an anti-IL-12/23p40 monoclonal antibody Distribution will be transferred to Mitsubishi Tanabe Pharma, while the two companies will continue co-promotion of STELARA to treat adults with Crohn’s disease in Japan
June 25		Corporate Governance Report
June 22		Notice of Resolution of the 11th Ordinary General Meeting of Shareholders ⇒Results of the Exercise of Voting Rights(June 25, 2018)
June 14		TFDA approves Clenafin/Jublia for the treatment of Onychomycosis in Taiwan
May 30		Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development―Start of collaborative/competitive drug discovery research by three academic institutions and three pharmaceutical companies
May 28		For the ALS patients in the world,we hope to deliver Japan-originated ALS treatment―EMA accepts our filing for Edaravone to treat ALS
May 25		Notice of Convocation of the 11th Ordinary General Meeting of Shareholders
May 18		Canagliflozin (Antidiabetic agent) wins The Technology Award Grand Prize fromthe Japan Chemical Industry Association (JCIA)
May 10		IR Meeting for FY2017 Business Results[Material][Video]
May 9		Announcement of Financial Results for FY2017 ⇒R&D Pipeline "State of New Product Development"
April 10		Update of Previous Disclosure ― Announcement of Filing a Request for Arbitration on the Licensing Agreement with Kolon Life Science
April 10		To ALS patients in the world, we hope to deliver Japan-originated ALS treatment―Health Canada accepts our filing for Edaravone to treat ALS and we established commercializing company in Canada
March 26		Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development
March 6		Name Change of our Singapore Subsidiary
March 1		Mitsubishi Tanabe Pharma Group started marketing CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitus in Taiwan
February 28		Valixa Tablet 450mg ―Public knowledge-based application for an additional pediatric indication for the prevention of CMV disease in organ transplant patients as well as application for an additional dosage form of dry syrup
February 5		IR Meeting for FY2017 3rd Quarter Business Results[Material][Audio]
February 5		Announcement of FY2017 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
January 23		Swissmedic accepts our filing for Edaravone to treat ALS ― To ALS patients in the world, we hope to deliver Japan-originated ALS treatment
January 16		Approval in China Received for Additional Novastan Indication for Acute Cerebral Infarction ― Reinforcing Our Pharmaceutical Development and Sales in China, the World's Second Largest Pharmaceutical Market
January 11		Launch of "KREMEZIN Tablets 500mg" (Additional Formulation), Drug for Chronic Renal Failure ― For Improving Patients' Usage Experience and Medication Adherence ―

Investor Relations

Top InterviewTalk about the "Medium-Term Management Plan 16-20"

IR Calendar

2018

What's New

2018

Top Interview
Talk about the "Medium-Term Management Plan 16-20"